Immune cells from donors show promise against Hard-to-Treat lymphoma
NCT ID NCT04673617
First seen Apr 15, 2026 · Last updated May 13, 2026 · Updated 6 times
Summary
This study tested an experimental therapy called AB-101, made from donor natural killer (NK) cells, in 45 people with B-cell non-Hodgkin lymphoma that returned or didn't respond to prior treatments. The goal was to see if AB-101 is safe and can shrink tumors when given alone or combined with other cancer drugs. The approach aims to control the disease rather than cure it, as ongoing management may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Artiva Clinical Trial Site
Birmingham, Alabama, 35249, United States
-
Artiva Clinical Trial Site
Tucson, Arizona, 85719, United States
-
Artiva Clinical Trial Site
Orange, California, 92868, United States
-
Artiva Clinical Trial Site
San Diego, California, 92093, United States
-
Artiva Clinical Trial Site
Gainesville, Florida, 32608, United States
-
Artiva Clinical Trial Site
Atlanta, Georgia, 30342, United States
-
Artiva Clinical Trial Site
Chicago, Illinois, 60612, United States
-
Artiva Clinical Trial Site
Iowa City, Iowa, 52242, United States
-
Artiva Clinical Trial Site
Wichita, Kansas, 67214, United States
-
Artiva Clinical Trial Site
Louisville, Kentucky, 40241, United States
-
Artiva Clinical Trial Site
Detroit, Michigan, 48201, United States
-
Artiva Clinical Trial Site
Lake Success, New York, 11042, United States
-
Artiva Clinical Trial Site
New York, New York, 11021, United States
-
Artiva Clinical Trial Site
Columbus, Ohio, 43214, United States
-
Artiva Clinical Trial Site
Portland, Oregon, 97239, United States
-
Artiva Clinical Trial Site
Philadelphia, Pennsylvania, 19107, United States
-
Artiva Clinical Trial Site
Philadelphia, Pennsylvania, 19111, United States
-
Artiva Clinical Trial Site
Providence, Rhode Island, 02903, United States
-
Artiva Clinical Trial Site
Dallas, Texas, 75246, United States
-
Artiva Clinical Trial Site
Salt Lake City, Utah, 84112, United States
-
Artiva Clinical Trial Site
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.